Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems, Biocrates Ink Co-marketing Pact

NEW YORK (GenomeWeb News) – Biocrates Life Sciences said today that it has forged a worldwide co-marketing agreement with Applied Biosystems focused on the metabolomics market.
 
Innsbruck, Austria-based Biocrates will promote ABI’s mass spectrometers for targeted metabolomics and for use in combination with its AbsoluteIDQ kits. In return, ABI will promote Biocrates’ AbsolteIDQ kits for targeted metabolomics in combination with its triple quadrupole and QTRAP series instruments.
 
Biocrates launched the AbsoluteIDQ kit at the recent Aanalytica meeting in Munich, Germany. The kits are initially available only in Europe, but the firm plans to expand sales to the US and eventually the rest of the world, it said.
 
“Metabolomics is a growing field expected to expand the market for mass spectrometers worldwide,” Tamara Bond, senior director of the pharmaceutical business at ABI, said in a statement.
 
The firms expect to jointly market the combined technologies at upcoming conferences including the American Society of Mass Spectrometry in Denver, Colo., next week.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.